SCHEMBL3490753

SCHEMBL3490753

CCCCCCCCN1C(=O)N(Cc2ccccc2)c2cc(Cl)cc(Cl)c2S1(=O)=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.40
CA12 O43570 1/20 0.39
CA9 Q16790 1/20 0.39
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
KDM4E B2RXH2 1/20 0.38
USP2 O75604 1/20 0.38
POLB P06746 1/20 0.38
RECQL P46063 1/20 0.38
BLM P54132 1/20 0.38
TP53 P04637 1/20 0.37
CNR2 P34972 2/20 0.36
HCRTR1 O43613 1/20 0.35
HCRTR2 O43614 1/20 0.35
ALDH1A1 P00352 1/20 0.35
CDC25B P30305 1/20 0.35
F2 P00734 1/20 0.35
PLG P00747 1/20 0.35
ELANE P08246 1/20 0.35
CTSG P08311 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3488509 1.00 MAPT (0.40) MAPTCA12CA9MEN1KMT2A
SCHEMBL3490463 0.96 MAPT (0.41) MAPTCA12CA9TP53HCRTR1
SCHEMBL3489072 0.91 MAPT (0.43) MAPTCA12CA9TP53HCRTR1
SCHEMBL3488912 0.87 MAPT (0.43) MAPTMEN1KMT2AKDM4EUSP2
SCHEMBL3489081 0.87 MAPT (0.43) MAPTMEN1KMT2AKDM4EUSP2
SCHEMBL3490252 0.87 MAPT (0.44) MAPTTP53HCRTR1HCRTR2ALDH1A1
SCHEMBL3490284 0.85 CA12 (0.40) MAPTCA12CA9MEN1KMT2A
SCHEMBL3489133 0.85 F2 (0.42) MAPTCA12CA9MEN1KMT2A
SCHEMBL3490819 0.85 MAPT (0.39) MAPTMEN1KMT2AKDM4ETP53
SCHEMBL3489276 0.85 HTR6 (0.39) MAPTMEN1KMT2AKDM4EUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100035866-A1 NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIAZIN-3ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2010-02-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100035866-A1 NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIAZIN-3ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME OPRD1, HTR6, HTR1D MAPT 2158/4885CA12 4883/4885CA9 4884/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.